Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC50 of 0.2 µM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity[1][3].